Baclofen is a muscle relaxant approved primarily for treating spasticity, the involuntary muscle tightness and spasms that follow conditions like multiple sclerosis, spinal cord injuries, and cerebral palsy. Beyond that core indication, clinicians prescribe it off-label for a surprisingly wide range of problems, from alcohol dependence and acid reflux to stubborn hiccups and certain types of facial nerve pain. The drug was originally designed in the 1960s as a treatment for epilepsy, but its muscle-relaxing properties turned out to be far more useful than its anticonvulsant ones, and that happy accident shaped its clinical life ever since.1ACS Chemical Neuroscience. Classics in Chemical Neuroscience: Baclofen
How Baclofen Works
Baclofen activates a specific type of receptor in the brain and spinal cord called the GABA-B receptor. GABA is the nervous system’s main calming chemical, and when baclofen binds to GABA-B receptors, it dials down nerve signaling in two ways. On the presynaptic side, it reduces the release of excitatory signals between nerve cells. On the postsynaptic side, it opens potassium channels that make the receiving neuron less likely to fire. Research on spinal cord neurons has confirmed both effects: baclofen cut the frequency of excitatory signals and produced outward potassium currents that quieted the cells.2PubMed Central. Molecular mechanisms of the antispasticity effects of baclofen on spinal ventral horn neurons The net result is that overactive motor circuits calm down, loosening tight muscles and reducing painful spasms.
One practical wrinkle: baclofen does not easily cross the blood-brain barrier when taken by mouth. The drug is absorbed well from the gut, but brain concentrations end up at less than a tenth of blood levels.3PubMed. Intrathecal baclofen. Experimental and pharmacokinetic studies That poor penetration is part of why oral doses need to be relatively high and why side effects can become a problem before spasticity is fully controlled. It also explains why a delivery method that bypasses the blood-brain barrier altogether became a major part of baclofen therapy.
Spasticity in Multiple Sclerosis
The condition baclofen is most associated with is spasticity from multiple sclerosis. MS damages nerve pathways that normally keep muscle tone in check, leaving patients with stiff limbs, painful spasms, and difficulty moving. In a controlled trial comparing baclofen with placebo, patients on the drug showed a significant reduction in spasticity, with the drug proving especially effective against flexor and extensor spasms and the pain that accompanies them.4PubMed. The use of baclofen in treatment of spasticity in multiple sclerosis For many people with MS, baclofen is the first medication tried when spasticity starts interfering with daily life.
Head-to-head comparisons with other antispasticity drugs suggest baclofen and tizanidine are roughly equivalent in how well they reduce spasticity, though they differ in their side-effect profiles. In one trial of MS patients, both clinicians and physiotherapists rated baclofen as superior on perceived efficacy and tolerance, though the patient-reported difference was not statistically significant.5PubMed. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis A systematic review confirmed the general picture: the two drugs are similarly effective, but baclofen tends to cause more muscle weakness while tizanidine causes more dry mouth and drowsiness.6PubMed. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review In practice, which one you end up on often depends on which side effects you tolerate better.
Cerebral Palsy and Pediatric Spasticity
Baclofen is widely used in children with cerebral palsy, where abnormal muscle tone can interfere with movement, posture, and even surgical outcomes. Oral baclofen is considered a first-line treatment for generalized hypertonia related to cerebral palsy, and increasing doses before surgery may improve outcomes with fewer long-term complications.7PubMed. Baclofen and Botulinum Toxin A Use in Tone Management for Children With Cerebral Palsy: A Review of Current Literature and Research Gaps in Pre- and Perioperative Care Dosing in children is typically based on body weight, with research supporting a regimen of about 2 mg per kilogram per day, escalated gradually.8PubMed Central. Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy
The evidence base for oral baclofen in pediatric cerebral palsy is, honestly, thinner than you might expect given how commonly the drug is prescribed. A systematic review of existing studies found conflicting evidence on whether oral baclofen actually reduces muscle tone or improves motor function in children and adolescents with spastic cerebral palsy, noting that the studies were generally underpowered and at serious risk of bias.9PubMed. Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy That does not mean the drug doesn’t work in these patients; rather, the controlled trials to definitively prove it have not been done at the quality needed. This is a common situation in pediatric neurology, where ethical and practical constraints make large randomized trials difficult.
Intrathecal Baclofen for Severe Cases
When oral baclofen cannot adequately control spasticity, or when its side effects become limiting, a surgical option exists: intrathecal baclofen therapy. This involves implanting a small programmable pump under the skin of the abdomen that delivers baclofen directly into the cerebrospinal fluid surrounding the spinal cord. By bypassing the blood-brain barrier entirely, intrathecal delivery achieves effective concentrations in the spinal cord at doses hundreds of times smaller than what would be needed orally.10PubMed Central. Intrathecal Baclofen Therapy: Pros and Cons
Intrathecal baclofen is typically reserved for severe spasticity of spinal or cerebral origin that has not responded to conservative treatment. It is used in both adults and children, including those with cerebral palsy, MS, and spinal cord injuries. The pump requires surgical implantation and regular refills, usually every few months. Complications can include pump malfunction, catheter kinking or migration, and infection at the surgical site. Perhaps the most serious risk is sudden baclofen withdrawal if the pump fails or runs dry, which can be a medical emergency, a topic covered in more detail below.
Alcohol Use Disorder
One of baclofen’s most talked-about off-label uses is for alcohol dependence. Interest in this application surged after a French cardiologist, Olivier Ameisen, publicly described using high-dose baclofen to control his own alcohol cravings, an account he eventually turned into a book. Since then, the idea has moved from personal anecdote into formal clinical research. To date, at least 15 randomized controlled trials have investigated baclofen for alcohol use disorder, including some testing doses above 100 mg per day.11PubMed Central. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
Early results were encouraging. A preliminary double-blind trial found that a higher percentage of patients in the baclofen group achieved total alcohol abstinence compared to placebo, with more cumulative abstinence days and reductions in both obsessive and compulsive components of craving.12Alcohol and Alcoholism. Baclofen Efficacy in Reducing Alcohol Craving and Intake: A Preliminary Double-Blind Randomized Controlled Study Clinical experience has also pointed in this direction, with chart reviews suggesting baclofen reduces craving and consumption even in patients with low motivation to quit.13PubMed Central. Clinical experience of baclofen in alcohol dependence: A chart review
That said, the picture is more complicated than the early enthusiasm suggested. Results across the larger body of trials have been mixed, with some showing clear benefits and others showing none. Dose appears to matter: some researchers believe that the low doses used in many early trials (typically 30 mg per day) were simply not enough, and that meaningfully higher doses may be necessary for people with severe dependence. France became the first country to formally approve baclofen for alcohol dependence, though most other regulatory agencies have not followed. If your doctor suggests baclofen for alcohol problems, it remains an off-label use in most of the world, and the optimal dose and patient selection are still being worked out.
Acid Reflux
Baclofen’s ability to tighten the lower esophageal sphincter, the muscular valve between the stomach and esophagus, has made it useful for a subset of people with gastroesophageal reflux disease. Reflux episodes often happen during transient lower esophageal sphincter relaxations, brief moments when the valve opens without a swallow. Baclofen was shown to significantly reduce these relaxations, postprandial acid reflux events, and acid-related symptoms in studies testing either single doses or short courses of treatment.14PubMed Central. The Role of Baclofen in the Treatment of Gastroesophageal Reflux Disease
In a controlled study of healthy volunteers, baclofen reduced the rate of reflux episodes by more than 60% and roughly halved the rate of transient sphincter relaxations, while modestly increasing the resting pressure of the sphincter.15PubMed. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects This makes baclofen particularly interesting for patients whose reflux does not respond well to proton pump inhibitors, which reduce acid production but do nothing about the sphincter relaxations themselves. In practice, baclofen is sometimes added on top of a PPI for stubborn reflux, though its side-effect profile limits its use as a frontline therapy.
Intractable Hiccups
Persistent hiccups, the kind that last for days, weeks, or even years, are far more than an annoyance. They can disrupt sleep, make eating difficult, and significantly erode quality of life. The causes range from nerve irritation and brain lesions to kidney failure and post-surgical complications. Baclofen has emerged as one of the more reliable treatments for this problem, and it is sometimes remarkably effective. In one reported case, a 36-year-old man who had suffered from intractable hiccups for five years found that a single oral dose of baclofen resolved them.16PubMed Central. Treatment of intractable hiccups with an oral agent monotherapy of baclofen -a case report- A case series involving multiple patients with persistent hiccups of various origins similarly concluded that baclofen is a promising treatment for this condition.17PubMed Central. Baclofen in the Treatment of Persistent Hiccup: A Case Series
The evidence here is mostly case reports and small series rather than large controlled trials, which is typical for treatments of uncommon conditions. But baclofen is now widely recognized as a go-to option when standard hiccup remedies fail, and many clinicians reach for it before trying more aggressive approaches like nerve blocks.
Trigeminal Neuralgia and Nerve Pain
Trigeminal neuralgia, a condition that causes sudden, severe, shock-like pain in the face, is notoriously difficult to treat. Carbamazepine is the traditional first-line drug, but some patients cannot tolerate it or find it stops working. Baclofen has been studied specifically in this population and shown real benefit. In a double-blind trial followed by an open trial in 50 patients who were refractory to or unable to tolerate carbamazepine, about three-quarters were relieved of their attacks by baclofen, either alone or in combination with previously ineffective doses of other anticonvulsants.18PubMed. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up
Beyond trigeminal neuralgia, baclofen is used as an adjuvant analgesic for other types of neuropathic pain, though the controlled evidence is strongest for the facial nerve pain indication.19PubMed. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review Clinicians sometimes combine it with other pain medications to improve control in patients whose nerve pain has not responded to more standard analgesics.
Where Baclofen Has Not Panned Out
Not every promising application has held up. Cocaine dependence is a case in point. Preclinical studies in animals suggested baclofen might reduce cocaine self-administration, which led to a multi-center clinical trial. The results were clearly negative: baclofen failed to increase cocaine-free days compared to placebo, and there were no significant differences in any of the secondary measures of cocaine use.20PubMed Central. Multi-Center Trial of Baclofen for Abstinence Initiation in Severe Cocaine Dependent Individuals This is a good reminder that animal models of addiction do not always translate to humans, and it highlights how different baclofen’s effects on alcohol cravings are from its effects on stimulant use.
Early-stage research has also explored whether arbaclofen, a more selective form of the molecule, might help with neurodevelopmental conditions. A phase 2 trial in children and adults with fragile X syndrome found some suggestive improvements in social behavior and avoidance, particularly in those with more severe social impairment, though the primary endpoints were not met.21PubMed. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial Later trials in both fragile X and autism spectrum disorder failed to replicate the promise, and the drug’s developer eventually halted the program. The hypothesis that GABA-B modulation could address excitatory-inhibitory imbalances in neurodevelopmental conditions remains interesting in theory, but clinical proof has been elusive.
Side Effects and Who Should Be Cautious
Baclofen is not a benign drug. Side effects are common with oral use, affecting somewhere between a quarter and three-quarters of patients. The most frequent complaints are drowsiness, muscle weakness, nausea, and tingling or numbness.22Journal of Rehabilitation Medicine. Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen The muscle weakness is a particular irony: a drug prescribed to loosen tight muscles can overshoot and leave patients feeling weak and unsteady. This is one of the key reasons clinicians titrate doses slowly upward and why intrathecal delivery, with its much lower effective doses, exists.
People with reduced kidney function face a special risk. Baclofen is primarily eliminated through the kidneys, and when kidney function declines, the drug accumulates to potentially toxic levels. Expert guidance recommends reducing the dose in patients with moderately reduced kidney function and avoiding baclofen altogether in patients with severely reduced kidney function or those on dialysis.23PubMed. Baclofen Toxicity in Kidney Disease Cases of baclofen toxicity in kidney disease patients have included severe sedation, respiratory depression, and coma. If you are on baclofen and your kidney function changes, your dose may need to be adjusted, so keep your prescriber in the loop.
The Danger of Abrupt Withdrawal
Perhaps the most important safety message about baclofen is this: do not stop it suddenly. Abrupt discontinuation, whether because a prescription lapsed, a pump malfunctioned, or a patient decided to quit on their own, can trigger a serious withdrawal syndrome. A systematic review of withdrawal cases found that symptoms commonly include severe psychiatric disturbances (affecting up to about one in five patients), delirium, agitation, and instability of heart rate, blood pressure, and temperature, typically appearing within one to four days of stopping the drug.24PubMed. Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review A separate review of published withdrawal cases confirmed that delirium was the dominant psychiatric presentation, more so than psychosis or other conditions.25PubMed. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies
In the worst scenarios, baclofen withdrawal can resemble severe alcohol withdrawal or benzodiazepine withdrawal, with seizures and life-threatening autonomic instability. The risk is highest in patients on high doses or those using intrathecal pumps, where a mechanical failure can cut off the drug supply without warning. Patients with intrathecal baclofen pumps are generally educated about the signs of withdrawal and told to treat pump alarms as emergencies. For anyone on oral baclofen, the takeaway is straightforward: if you need to stop the drug, taper down gradually under medical supervision.
How Baclofen Compares to Other Antispasticity Drugs
Baclofen, tizanidine, and dantrolene are the three most commonly used oral drugs for spasticity, and they work through different mechanisms. Baclofen acts in the central nervous system at GABA-B receptors. Tizanidine is a central alpha-2 adrenergic agonist that reduces excitatory nerve activity. Dantrolene works directly on skeletal muscle, interfering with calcium release inside muscle fibers. The evidence comparing them is somewhat limited, but what exists suggests baclofen and tizanidine are roughly equivalent in their ability to reduce spasticity, while there is insufficient data to clearly place dantrolene relative to either one.26PubMed. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review
Some analyses have suggested baclofen has a more favorable serious-complication profile compared to tizanidine, which has been associated with liver enzyme elevations requiring monitoring.27PubMed Central. Oral Antispasticity Drugs and Non-Progressive Neurological Diseases: A Meta-Analysis on Safety and Efficacy In practice, drug choice often comes down to a trial-and-error process: you start one, see how you respond, and switch if side effects are intolerable or the spasticity relief is insufficient. Many patients cycle through multiple options before finding the right fit, and combination regimens are not unusual in severe cases.
Practical Considerations for People Taking Baclofen
If you are starting baclofen, expect a gradual dose escalation. Doctors typically begin at a low dose, often 5 mg three times a day, and increase every few days based on response and tolerance. The slow ramp-up helps your body adjust and minimizes drowsiness and dizziness in the early days. Taking the medication with food can reduce stomach upset. Alcohol should be avoided or minimized, as both substances depress the central nervous system and their combination magnifies sedation.
Driving and operating machinery deserve special caution, particularly during the first few weeks or after a dose increase. Drowsiness is one of the most common side effects, and it can be more pronounced than you expect. If you have been stable on baclofen for weeks and your alertness feels normal, driving is generally considered acceptable, but you should reassess after any dosage change.
For patients with intrathecal pumps, the practical realities are different. The pump reservoir needs refilling every one to six months, depending on the dose and pump capacity. You will carry a card identifying you as a pump patient, and you will be educated about alarm signals from the device. MRI scans require coordination with the pump team, as some pump models need to be adjusted or interrogated before and after imaging. Travel planning should account for pump refill schedules, and carrying documentation about the implanted device is wise for airport security and hospital visits in unfamiliar places.